SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals reports 76% jump in Q3 net profit

11 Feb 2016 Evaluate

GlaxoSmithKline Pharmaceuticals has reported results for third quarter ended December 31, 2015.  

The company has reported 76.38% rise in its net profit at Rs 79.90 crore for the quarter ended December 31, 2015 as compared to Rs 45.30 crore for the same quarter in the previous year. Total income of the company has increased by 10.66% to Rs 762.06 crore for the quarter under review from Rs 688.63 crore for the corresponding quarter of the previous year.  

GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Glaxosmithkline Phar Share Price

2451.80 32.70 (1.35%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×